During the past decade, Oslo Myeloma Center - PPDS conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Oslo Myeloma Center - PPDS" are "Colorectal Cancer" (1 trials) and "Melanoma" (1 trials). Many other conditions were trialed in "Oslo Myeloma Center - PPDS" in a lesser frequency.

Most popular intervention types in "Oslo Myeloma Center - PPDS" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "LGX818" (2 trials), "BYL719" (1 trials), "Cetuximab" (1 trials), "MEK162" (1 trials) and "vemurafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oslo Myeloma Center - PPDS" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Oslo Myeloma Center - PPDS". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Oslo Myeloma Center - PPDS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Oslo Myeloma Center - PPDS, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".